Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Lung Cancer

Free Subscription 06.04.2026 1 Ann Surg Oncol 2 Anticancer Res 1 Arch Bronconeumol 6 BMC Cancer 2 Br J Cancer 1 Cancer Epidemiol Biomarkers Prev 2 Cancer Res 6 Cancer Sci 2 Clin Lung Cancer 3 Clin Nucl Med 1 Epidemiology 2 Int J Cancer 1 Int J Radiat Oncol Biol Phys 2 J Thorac Cardiovasc Surg 5 J Thorac Oncol 3 Lancet Oncol 4 Lung Cancer 1 Mol Carcinog 1 Nat Med 1 Oncogene 1 PLoS One

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Ann Surg Oncol

1. SINGH A, Xie Y, McAllister MA, Mazzola E, et al
   ASO Visual Abstract: Multifactorial Impact of Age, Race and Female Sex on Management of Non-small Cell Lung Cancer.
   Ann Surg Oncol. 2026 Mar 31. doi: 10.1245/s10434-026-19573.
   PubMed        
   
   

   
   Anticancer Res

2. DELA CRUZ MC, Yao X, Nealy A, Bailey J, et al
   BIT1 as an Effector of EGFR-TKI-induced Apoptosis via TLE1 Inhibition in Lung Adenocarcinoma Cells.
   Anticancer Res. 2026;46:1799-1818.
   PubMed         Abstract available
   
   
3. PRAMUALSIN T, Ei ZZ, Racha S, Sriratanasak N, et al
   Chemosensitizing Effects of Resveratrol Derivatives on p53-dependent Apoptosis Triggered by Cisplatin in Human Lung Cancer Cells.
   Anticancer Res. 2026;46:1893-1901.
   PubMed         Abstract available
   
   

   
   Arch Bronconeumol

4. SANCHEZ-CUCO A, Suarez M, Santisteve S, Vila A, et al
   Screened vs. Non-Screened Lung Cancer: Real-World Evidence of a Stage Shift.
   Arch Bronconeumol. 2026 Mar 14:S0300-2896(26)00088.
   PubMed        
   
   

   
   BMC Cancer

5. WU S, Zeng L, Li Y
   Single-cell hdWGCNA and experimental validation identify an innovative T-cell-associated prognostic model and immune microenvironment in lung adenocarcinoma with lymph node metastasis.
   BMC Cancer. 2026;26:426.
   PubMed         Abstract available
   
   
6. ZHANG D, Shi Y, Liu X, Gao X, et al
   Sensitivity of different epidermal growth factor receptor (EGFR) exon 19 deletion subtypes to first-line osimertinib in Chinese non-small cell lung cancer patients.
   BMC Cancer. 2026 Mar 30. doi: 10.1186/s12885-026-15908.
   PubMed        
   
   
7. ROSENBERGER A, Bickeboller H, Christiani DC, Caporaso NE, et al
   Genes associated with genetic and rare lung diseases and the risk of lung cancer.
   BMC Cancer. 2026 Apr 1. doi: 10.1186/s12885-026-15934.
   PubMed        
   
   
8. CHEN YF, Zhang CL, Li Y, Liu CF, et al
   Serum exosomal miR-192-5p as a novel predictive biomarker for immunochemotherapy response in advanced non-small cell lung cancer.
   BMC Cancer. 2026 Apr 1. doi: 10.1186/s12885-026-15946.
   PubMed        
   
   
9. TURCOTT JG, Palomares-Palomares CB, Rios-Garcia E, Cardenas-Fernandez D, et al
   Role of cachexia in advanced non-small cell lung cancer patients treated with EGFR-TKIS.
   BMC Cancer. 2026 Apr 2. doi: 10.1186/s12885-026-15773.
   PubMed        
   
   
10. YE L, Lou L, Yin Z, He T, et al
    Efficacy and safety of thoracoscopic photodynamic therapy combined with 5% ethanol-cisplatin intrapleural perfusion in the treatment of malignant pleural effusion in non-small cell lung cancer.
    BMC Cancer. 2026 Apr 2. doi: 10.1186/s12885-026-15919.
    PubMed        
    
    

    
    Br J Cancer

11. JOHNSON ML, Fabbri G, Ciardullo C, Wang JS, et al
    Treatment monitoring by biomarker analysis in a Phase I dose-expansion study of AZD2811 for relapsed/refractory small-cell lung cancer.
    Br J Cancer. 2026 Apr 3. doi: 10.1038/s41416-026-03414.
    PubMed         Abstract available
    
    
12. ZHANG J, Liu Y, Yuan H, Zhan N, et al
    Molecular phenotypes stratify small cell lung cancer for targeted therapy and immunotherapy.
    Br J Cancer. 2026 Apr 3. doi: 10.1038/s41416-026-03390.
    PubMed         Abstract available
    
    

    
    Cancer Epidemiol Biomarkers Prev

13. JI J, Xue R, Zhang X, Yang M, et al
    Early Lung Cancer Detection Using Nucleotide Transition Probabilities in Plasma Cell-Free DNA.
    Cancer Epidemiol Biomarkers Prev. 2026 Apr 3. doi: 10.1158/1055-9965.EPI-25-2034
    PubMed         Abstract available
    
    

    
    Cancer Res

14. ZENG J, Li Q, Zhang J, Yu Z, et al
    KLF5 Activation Promotes Malignant Transformation to Drive Development of Lung Squamous Cell Carcinoma.
    Cancer Res. 2026;86:1622-1638.
    PubMed         Abstract available
    
    
15. XING B, Liu J, Xie Y, Liu P, et al
    LINE-1 Retrotransposon Protein ORF1p Forms Condensates That Drive cGAS-Induced Immune Evasion in Lung Squamous Cell Carcinoma.
    Cancer Res. 2026;86:1657-1675.
    PubMed         Abstract available
    
    

    
    Cancer Sci

16. KESHARWANI P, Nasir N, Wahab S, Gupta G, et al
    PEGylated Chitosan Nanoparticles: Engineering Multifunctional Platforms for Targeted Cervical and Lung Cancer Treatment.
    Cancer Sci. 2026 Mar 31. doi: 10.1111/cas.70361.
    PubMed         Abstract available
    
    
17. MOURI A, Kagamu H, Tamada K, Nishio M, et al
    Analysis of Peripheral T Cell Profiling and Plasma Proteomics in Advanced NSCLC Patients Treated With Atezolizumab.
    Cancer Sci. 2026;117:904-916.
    PubMed         Abstract available
    
    
18. MATSUMOTO K, Naito Y, Shiroyama T, Tamiya M, et al
    Impact of Sequential Ramucirumab Plus Docetaxel After PD-1 Inhibitors on Anti-PD-1 Antibody-Bound T-Cell Dynamics and Clinical Outcomes.
    Cancer Sci. 2026;117:929-942.
    PubMed         Abstract available
    
    
19. MURASE Y, Nanjo S, Arai S, Kondo S, et al
    Therapeutic Strategies to Overcome Payload Resistance of Trastuzumab Deruxtecan in HER2-Positive Cancers.
    Cancer Sci. 2026;117:996-1009.
    PubMed         Abstract available
    
    
20. LEE JS, Sugawara S, Kang JH, Kim HR, et al
    Four-Year Outcomes for Nivolumab With Chemotherapy and Bevacizumab in Patients With Nonsquamous NSCLC in the TASUKI-52.
    Cancer Sci. 2026;117:1124-1135.
    PubMed         Abstract available
    
    
21. YOSHIDA A, Abe S, Izumi T, Itakura S, et al
    Cancer-Specific Antihuman Podoplanin Antibody chLpMab-2f Exerts Antitumor Effects Against Pleural Mesothelioma.
    Cancer Sci. 2026;117:917-928.
    PubMed         Abstract available
    
    

    
    Clin Lung Cancer

22. YU XQ, David M, Ngo P, Vaneckova P, et al
    Evaluating Prognostic Factors for Sex Differences in Lung Cancer Survival: A Retrospective Analysis of Real-World Data in Australia.
    Clin Lung Cancer. 2026 Mar 9:S1525-7304(26)00035.
    PubMed         Abstract available
    
    
23. IWASAKI M, Ando T, Fujii K, Watanabe K, et al
    Clinicogenomic Predictors of First-line Immune Checkpoint Inhibitor Outcomes in Non-Small Cell Lung Cancer: A Nationwide CCAT Cohort From Japan.
    Clin Lung Cancer. 2026 Mar 10:S1525-7304(26)00037.
    PubMed         Abstract available
    
    

    
    Clin Nucl Med

24. TANG P, Yang L, Tian R
    Invasive Adenocarcinoma and Clear Cell Stromal Tumor Coexisting in FDG-Avid Pulmonary Cystic Lesions.
    Clin Nucl Med. 2026;51:e342-e343.
    PubMed         Abstract available
    
    
25. ZHANG J, Dong A, Wang Y
    FDG PET/MRI and PET/CT Findings in a Case of Lung Metastases From Infantile Fibrosarcoma Harboring LMNA-NTRK1 Gene Fusion.
    Clin Nucl Med. 2025 Dec 11. doi: 10.1097/RLU.0000000000006261.
    PubMed         Abstract available
    
    
26. DUPONT AC, Farges M, Chapelle B, Cancel M, et al
    From One Cancer to Two: [(1)(8)F]FES PET/CT Redirected Diagnosis and Therapy in a Metastatic Breast Cancer Patient.
    Clin Nucl Med. 2026 Feb 23. doi: 10.1097/RLU.0000000000006386.
    PubMed         Abstract available
    
    

    
    Epidemiology

27. BENITEZ-AURIOLES J, Joules A, Brusini I, Peek N, et al
    Understanding Algorithmic Fairness for Clinical Prediction in Terms of Subgroup Net Benefit and Health Equity.
    Epidemiology. 2026;37:386-396.
    PubMed         Abstract available
    
    

    
    Int J Cancer

28. VANSTRAELEN S, Reiner A, Tan KS, Mastrogiacomo B, et al
    Somatic copy number variation as a prognostic marker for recurrence in never-smokers with early-stage lung adenocarcinoma.
    Int J Cancer. 2026;158:2900-2911.
    PubMed         Abstract available
    
    
29. HAFEEZ KS, Debernardi C, Allione A, Herman EJ, et al
    Integrating polygenic and methylation risk scores for pleural mesothelioma risk stratification.
    Int J Cancer. 2026;158:2866-2879.
    PubMed         Abstract available
    
    

    
    Int J Radiat Oncol Biol Phys

30. LEVIN N, Killingberg KT, Halvorsen TO, Danielsen S, et al
    Erratum to 'Evaluation of Radiation Therapy Treatment Plans in a Randomized Phase 2 Trial Comparing 2 Schedules of Twice-Daily Thoracic Radiation Therapy in Limited Stage Small Cell Lung Cancer.' International Journal of Radiation Oncology*Biology*Phy
    Int J Radiat Oncol Biol Phys. 2026 Apr 3:S0360-3016(26)00512.
    PubMed        
    
    

    
    J Thorac Cardiovasc Surg

31. JIN KQ, Wu YM, Zhou B, Shen YR, et al
    Safety and efficiency of supervised sequentially overlapping video-assisted thoracoscopic lobectomies in a high-volume center.
    J Thorac Cardiovasc Surg. 2026;171:815-825.
    PubMed         Abstract available
    
    
32. WANG D, Fang Z, Zhu A, Rettner B, et al
    Changes in patient-reported quality of life after lobectomy versus sublobar resection.
    J Thorac Cardiovasc Surg. 2026;171:826-835.
    PubMed         Abstract available
    
    

    
    J Thorac Oncol

33. RUSSO A, Javey M, Huang RSP, Yaung SJ, et al
    Molecular Profiling across 80,000 Patients with Lung Cancer.
    J Thorac Oncol. 2026 Mar 26:103695. doi: 10.1016/j.jtho.2026.103695.
    PubMed         Abstract available
    
    
34. FUKUDA A, Fukami T, Nomura K, Kashima J, et al
    Brief Report: Low Delta-like Ligand 3 expression and T Cell Exhaustion Drive Resistance to Tarlatamab combined with anti-PD-1 in Small-Cell Lung Cancer.
    J Thorac Oncol. 2026 Mar 26:103693. doi: 10.1016/j.jtho.2026.103693.
    PubMed         Abstract available
    
    
35. PARISI C, De Giglio A, Banini M, Tagliamento M, et al
    Non-Small Cell Lung Cancer (NSCLC) in Vulnerable and Special Populations: Towards Personalized Care.
    J Thorac Oncol. 2026 Mar 30:103705. doi: 10.1016/j.jtho.2026.103705.
    PubMed         Abstract available
    
    
36. STOCKHAMMER P, El Zarif T, Schillo JL, Li F, et al
    ERBB2 activating mutations and co-occurring genomic alterations contribute to disease heterogeneity in patients with ERBB2-mutant lung cancer.
    J Thorac Oncol. 2026 Apr 1:103708. doi: 10.1016/j.jtho.2026.103708.
    PubMed         Abstract available
    
    
37. LU J, Shum E, Samstein RM, Prada D, et al
    Lung Cancer in Never Smokers: Genetics, Epidemiology, Environmental Exposures, and Distinct Immune Landscape.
    J Thorac Oncol. 2026 Apr 1:103709. doi: 10.1016/j.jtho.2026.103709.
    PubMed         Abstract available
    
    

    
    Lancet Oncol

38. GREGORC V, Majem M, Lo Russo G, Maio M, et al
    Fulzerasib plus cetuximab in first-line KRAS(G12C)-mutated non-small-cell lung cancer (KROCUS): a single-arm, multicentre, phase 1b/2 trial.
    Lancet Oncol. 2026;27:432-441.
    PubMed         Abstract available
    
    
39. EL SAADANY T, Sacher A
    KRAS(G12C) inhibitor combination therapy in metastatic non-small-cell lung cancer: choosing the right path.
    Lancet Oncol. 2026;27:396-397.
    PubMed        
    
    
40. GORRIA T, Mezquita L
    Beyond monotherapy: chemotherapy-free strategies in first-line advanced non-small-cell lung cancer.
    Lancet Oncol. 2026;27:394-395.
    PubMed        
    
    

    
    Lung Cancer

41. KNAPP B, Waqar SN, Ward JP, Herzog BH, et al
    Evaluating the safety and efficacy of chemotherapy in patients with relapsed small cell lung cancer combined with allopurinol and MycoPhenolate (CLAMP).
    Lung Cancer. 2026;215:109382.
    PubMed         Abstract available
    
    
42. LIN JT, Yang XN, Li XM, Zhang C, et al
    Adjuvant immunotherapy may have no impact on survival in patients who received neoadjuvant immunotherapy for stage II-IIIB non-small cell lung cancer.
    Lung Cancer. 2026;215:109389.
    PubMed         Abstract available
    
    
43. COOPER AJ, Liang J, McDonald S, Arfe A, et al
    Real-world multi-institution analysis of tarlatamab in patients with small cell lung cancer.
    Lung Cancer. 2026;216:109390.
    PubMed         Abstract available
    
    
44. VICENTE-VALOR J, Aguado C, Mateos M, Tesolato S, et al
    Microbiota biomarkers as predictors on immunotherapy response in patients with advanced non-small cell lung cancer.
    Lung Cancer. 2026;216:109381.
    PubMed         Abstract available
    
    

    
    Mol Carcinog

45. SU G, Yang S, Fan B, Jiang Z, et al
    Long Non-Coding RNA PTPRG-AS1 Promotes Proliferation, Migration, and Invasion of Non-Small Cell Lung Cancer Cells via Modulation of the IGF1/PI3K/AKT Signaling Pathway.
    Mol Carcinog. 2026 Mar 30. doi: 10.1002/mc.70073.
    PubMed         Abstract available
    
    

    
    Nat Med

46. CHO BC, Balaraman R, Chen HJ, Yu X, et al
    Gotistobart or docetaxel in metastatic squamous non-small cell lung cancer: stage 1 of the randomized phase 3 PRESERVE-003 trial.
    Nat Med. 2026 Mar 27. doi: 10.1038/s41591-026-04323.
    PubMed         Abstract available
    
    

    
    Oncogene

47. ZHANG R, Li Y, Lu H, Wang X, et al
    OTUB1/CDYL axis-mediated epigenetic repression of SOX18 facilitates lung cancer progression by inhibiting FDX1-dependent cuproptosis.
    Oncogene. 2026 Mar 30. doi: 10.1038/s41388-026-03748.
    PubMed         Abstract available
    
    

    
    PLoS One

48. GEIER M, Amrane K, Bourhis D, Le Roux PY, et al
    PRognostic and predictive potential Of multiparametric dynamic whole-body 18F-FDG PET Imaging using a Long axial field-of-view (LAFOV) system for FIRST-line chemo-immunotherapy efficacy in advanced non-small cell lung cancer: PROFIL-1 study protocol.
    PLoS One. 2026;21:e0345990.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum